The priority list for the Pfizer vaccine - and how it will be rolled out (UK)

The priority list for the Pfizer vaccine - and how it will be rolled out 

Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI, 2 December 2020

‘Immunity Passports’ Exist, But Are They a Bad Idea?

‘Immunity Passports’ Exist, But Are They a Bad Idea? It might seem counterintuitive that, instead of needing a negative COVID-19 test to cross international borders, you could offer proof that you’d previously tested positive? Yet, these so-called ‘immunity passport’ policies already exist in certain countries, operating on the assumption that, having been infected and recovered, a person can’t contract or carry the virus again.

COVID-19 situation update for the EU/EEA and the UK, as of 7 December 2020

COVID-19 situation update for the EU/EEA and the UK: As of 07 December 2020, 14 080 951 cases have been reported in the EU/EEA and the UK: Portugal (322 474).

As of 07 December 2020, 349 316 deaths have been reported in the EU/EEA and the UK: Portugal (4 963)

What you need to know about the coronavirus pandemic on 7 December

COVID-19: What you need to know about the coronavirus pandemic on 7 December: Top stories: Increased restrictions and testing in South Korea; Pandemic still has a 'long way to run': WHO; Britain prepares roll out of Pfizer/BioNTech vaccine.

Monulparivir, the drug that "completely" stops the spread of coronavirus in 24 hours

Monulparivir, the drug that "completely" stops the spread of coronavirus in 24 hours: The COVID-19 vaccine may spell the end of the pandemic, but while mass vaccination is not available it is vital to stop community transmission. The new antiviral drug MK-4482 / EIDD-2801 or Molnupiravir, has managed to suppress "completely" the transmission of the coronavirus in just 24 hours , according to studies by the Institute of Biomedical Sciences of Georgia State University. 

 "This is the first demonstration of an orally available drug that quickly blocks the transmission of SARS-CoV-2 , so it could be a game changer," the researchers explained in the work published in the journal Nature Microbiology . 

The antiviral drug was developed at Emory University in Atlanta by the drug innovation company Drug Innovation Ventures at Emory (DRIVE), which was licensed by Ridgeback Biotherapeutics, which partnered with Merck & Co. Molnupiravir was originally designed to treat the flu and prevent the virus from making copies of itself, creating errors during viral RNA replication.